Efficacy and safety of a therapeutic interchange from high-dose calcium channel blockers to a fixed-dose combination of amlodipine/benazepril in patients with moderate-to-severe hypertension

Daniel E. Hilleman, A. P. Reyes, R. L. Wurdeman, Michele A. Faulkner

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Background: Recent hypertension trials have demonstrated the importance of achieving goal blood pressures to reduce the risk of target organ damage. In patients with moderate to severe hypertension, the use of high-dose monotherapy and/or combinations of drugs are necessary to achieve these goals. Fixed-dose combination products may be useful in these patients by reducing the number of daily doses required to control blood pressure. Objective: The objective of the present study was to evaluate the efficacy and safety of a therapeutic interchange between high-dose calcium channel blocker therapy and a fixed-dose combination of amlodipine/benazepril (Lotrel®; Novartis Pharmaceuticals, USA) in patients with moderate to severe hypertension. Methods: A total of 75 patients were switched from amlodipine (n = 25), felodipine (n = 25), and nifedipine-GITS (n = 25) to amlodipine/benazepril. Twenty-eight of the 75 patients (37%) were taking either a beta-blocker or a diuretic in addition to the high-dose calcium channel blocker prior to the switch. Blood pressure control, side effects and the cost of the therapeutic interchange were evaluated in the year following the therapeutic interchange. Results: Sixty-six of the 75 (88%) patients were successfully switched with maintenance of blood pressure control and without the development of new dose-limiting side effects. Reasons for treatment failure after the therapeutic interchange included loss of blood pressure control in five patients and the development of new dose-limiting side effects in four patients. These side effects included cough in three patients and rash in one patient. After accounting for differences in drug acquisition cost and costs related to the switch (clinic and emergency room and laboratory tests), a cost savings of $16 030 for all 75 patients was realised in the first year. The per patient-per year cost savings was $214. Conclusions: Our data indicate that a therapeutic interchange from selected high-dose calcium channel blockers to a fixed-dose combination of amlodipine/benazepril can be successfully accomplished in the majority of patients.

Original languageEnglish
Pages (from-to)559-565
Number of pages7
JournalJournal of Human Hypertension
Volume15
Issue number8
DOIs
StatePublished - 2001

Fingerprint

Amlodipine
Calcium Channel Blockers
Hypertension
Safety
Therapeutics
Blood Pressure
Cost Savings
benazepril
Felodipine
Costs and Cost Analysis
Drug Costs
Therapeutic Uses
Drug Combinations
Nifedipine
Exanthema
Treatment Failure
Diuretics
Cough
Hospital Emergency Service

All Science Journal Classification (ASJC) codes

  • Internal Medicine

Cite this

@article{e844cdaee427446582b11350c7081090,
title = "Efficacy and safety of a therapeutic interchange from high-dose calcium channel blockers to a fixed-dose combination of amlodipine/benazepril in patients with moderate-to-severe hypertension",
abstract = "Background: Recent hypertension trials have demonstrated the importance of achieving goal blood pressures to reduce the risk of target organ damage. In patients with moderate to severe hypertension, the use of high-dose monotherapy and/or combinations of drugs are necessary to achieve these goals. Fixed-dose combination products may be useful in these patients by reducing the number of daily doses required to control blood pressure. Objective: The objective of the present study was to evaluate the efficacy and safety of a therapeutic interchange between high-dose calcium channel blocker therapy and a fixed-dose combination of amlodipine/benazepril (Lotrel{\circledR}; Novartis Pharmaceuticals, USA) in patients with moderate to severe hypertension. Methods: A total of 75 patients were switched from amlodipine (n = 25), felodipine (n = 25), and nifedipine-GITS (n = 25) to amlodipine/benazepril. Twenty-eight of the 75 patients (37{\%}) were taking either a beta-blocker or a diuretic in addition to the high-dose calcium channel blocker prior to the switch. Blood pressure control, side effects and the cost of the therapeutic interchange were evaluated in the year following the therapeutic interchange. Results: Sixty-six of the 75 (88{\%}) patients were successfully switched with maintenance of blood pressure control and without the development of new dose-limiting side effects. Reasons for treatment failure after the therapeutic interchange included loss of blood pressure control in five patients and the development of new dose-limiting side effects in four patients. These side effects included cough in three patients and rash in one patient. After accounting for differences in drug acquisition cost and costs related to the switch (clinic and emergency room and laboratory tests), a cost savings of $16 030 for all 75 patients was realised in the first year. The per patient-per year cost savings was $214. Conclusions: Our data indicate that a therapeutic interchange from selected high-dose calcium channel blockers to a fixed-dose combination of amlodipine/benazepril can be successfully accomplished in the majority of patients.",
author = "Hilleman, {Daniel E.} and Reyes, {A. P.} and Wurdeman, {R. L.} and Faulkner, {Michele A.}",
year = "2001",
doi = "10.1038/sj.jhh.1001230",
language = "English",
volume = "15",
pages = "559--565",
journal = "Journal of Human Hypertension",
issn = "0950-9240",
publisher = "Nature Publishing Group",
number = "8",

}

TY - JOUR

T1 - Efficacy and safety of a therapeutic interchange from high-dose calcium channel blockers to a fixed-dose combination of amlodipine/benazepril in patients with moderate-to-severe hypertension

AU - Hilleman, Daniel E.

AU - Reyes, A. P.

AU - Wurdeman, R. L.

AU - Faulkner, Michele A.

PY - 2001

Y1 - 2001

N2 - Background: Recent hypertension trials have demonstrated the importance of achieving goal blood pressures to reduce the risk of target organ damage. In patients with moderate to severe hypertension, the use of high-dose monotherapy and/or combinations of drugs are necessary to achieve these goals. Fixed-dose combination products may be useful in these patients by reducing the number of daily doses required to control blood pressure. Objective: The objective of the present study was to evaluate the efficacy and safety of a therapeutic interchange between high-dose calcium channel blocker therapy and a fixed-dose combination of amlodipine/benazepril (Lotrel®; Novartis Pharmaceuticals, USA) in patients with moderate to severe hypertension. Methods: A total of 75 patients were switched from amlodipine (n = 25), felodipine (n = 25), and nifedipine-GITS (n = 25) to amlodipine/benazepril. Twenty-eight of the 75 patients (37%) were taking either a beta-blocker or a diuretic in addition to the high-dose calcium channel blocker prior to the switch. Blood pressure control, side effects and the cost of the therapeutic interchange were evaluated in the year following the therapeutic interchange. Results: Sixty-six of the 75 (88%) patients were successfully switched with maintenance of blood pressure control and without the development of new dose-limiting side effects. Reasons for treatment failure after the therapeutic interchange included loss of blood pressure control in five patients and the development of new dose-limiting side effects in four patients. These side effects included cough in three patients and rash in one patient. After accounting for differences in drug acquisition cost and costs related to the switch (clinic and emergency room and laboratory tests), a cost savings of $16 030 for all 75 patients was realised in the first year. The per patient-per year cost savings was $214. Conclusions: Our data indicate that a therapeutic interchange from selected high-dose calcium channel blockers to a fixed-dose combination of amlodipine/benazepril can be successfully accomplished in the majority of patients.

AB - Background: Recent hypertension trials have demonstrated the importance of achieving goal blood pressures to reduce the risk of target organ damage. In patients with moderate to severe hypertension, the use of high-dose monotherapy and/or combinations of drugs are necessary to achieve these goals. Fixed-dose combination products may be useful in these patients by reducing the number of daily doses required to control blood pressure. Objective: The objective of the present study was to evaluate the efficacy and safety of a therapeutic interchange between high-dose calcium channel blocker therapy and a fixed-dose combination of amlodipine/benazepril (Lotrel®; Novartis Pharmaceuticals, USA) in patients with moderate to severe hypertension. Methods: A total of 75 patients were switched from amlodipine (n = 25), felodipine (n = 25), and nifedipine-GITS (n = 25) to amlodipine/benazepril. Twenty-eight of the 75 patients (37%) were taking either a beta-blocker or a diuretic in addition to the high-dose calcium channel blocker prior to the switch. Blood pressure control, side effects and the cost of the therapeutic interchange were evaluated in the year following the therapeutic interchange. Results: Sixty-six of the 75 (88%) patients were successfully switched with maintenance of blood pressure control and without the development of new dose-limiting side effects. Reasons for treatment failure after the therapeutic interchange included loss of blood pressure control in five patients and the development of new dose-limiting side effects in four patients. These side effects included cough in three patients and rash in one patient. After accounting for differences in drug acquisition cost and costs related to the switch (clinic and emergency room and laboratory tests), a cost savings of $16 030 for all 75 patients was realised in the first year. The per patient-per year cost savings was $214. Conclusions: Our data indicate that a therapeutic interchange from selected high-dose calcium channel blockers to a fixed-dose combination of amlodipine/benazepril can be successfully accomplished in the majority of patients.

UR - http://www.scopus.com/inward/record.url?scp=0034888766&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034888766&partnerID=8YFLogxK

U2 - 10.1038/sj.jhh.1001230

DO - 10.1038/sj.jhh.1001230

M3 - Article

VL - 15

SP - 559

EP - 565

JO - Journal of Human Hypertension

JF - Journal of Human Hypertension

SN - 0950-9240

IS - 8

ER -